Advertisement

Central European Journal of Chemistry

, Volume 10, Issue 5, pp 1464–1474 | Cite as

Cytostatic and cytotoxic properties of monensic acid and its biometal(II) complexes against human tumor / non-tumor cell lines

  • Radostina I. Alexandrova
  • Tanya Zhivkova
  • Marin Alexandrov
  • Georgi Miloshev
  • Milena Georgieva
  • Ivayla N. PantchevaEmail author
  • Mariana Io. Mitewa
Research Article
  • 69 Downloads

Abstract

The anticancer activity of monensic acid (MonH) and its biometal(II) complexes [M(Mon)2(H2O)2](M = Mg, Ca, Mn, Co, Ni, Zn) was evaluated against cultured human permanent cell lines established from glioblastoma multiforme (8MGBA) and cancers of the lung (A549), breast (MCF-7), uterine cervix (HeLa) and liver (HepG2). The viability and proliferation of the non-tumor human embryonic cell line Lep3 was also tested. The investigations were carried out using a thiazolyl blue tetrazolium bromide test, neutral red uptake cytotoxicity assay, crystal violet staining, colony forming method and double staining with acridin orange and propidium iodide. The results obtained reveal that the compounds applied at concentrations of 0.5–25 µg mL−1 for 24–72 h decrease the viability and proliferation of the treated cells in a time- and concentration-dependent manner. The metal(II) complexes studied (especially those of Co(II), Ni(II) and Zn(II)) have been found to express stronger cytotoxic and cytostatic activities than the non-coordinated monensic acid. The non-tumor human cell line showed strong chemosensitivity towards compounds tested comparable to that of cultured human tumor cell lines.

Keywords

Human cancer cell lines Monensin biometal(II) complexes Cytotoxic / Antiproliferative effect 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    A. Agtarap, J.W. Chamberlin, M. Pinkerton, L.K. Steinrauf, J. Am. Chem. Soc. 89, 5737 (1967)CrossRefGoogle Scholar
  2. [2]
    B.C. Pressman, Ann. Rev. Biochem. 45, 501 (1976)CrossRefGoogle Scholar
  3. [3]
    P.H. Stern, Clin. Orthop. Rel. Res. 122, 273 (1977)Google Scholar
  4. [4]
    P.C. Augustine, C.K. Smith, H.D. Danforth, M.D. Ruff, Poultry Sci. 66, 960 (1987)CrossRefGoogle Scholar
  5. [5]
    S.D. Folz, B.L. Lee, L.H. Nowakowski, G.A. Conder, Vet. Parasit. 28, 1 (1988)CrossRefGoogle Scholar
  6. [6]
    D.A. Kevin II, D.A.F. Meujo, M.T. Hamann, Exp. Opi. Drug Discov. 4, 109 (2009)CrossRefGoogle Scholar
  7. [7]
    B.G. Cox, N. van Truong, J. Rzeszotarska, H. Schneider, J. Chem. Soc., Faraday Trans. I 80, 3275 (1984)CrossRefGoogle Scholar
  8. [8]
    M. Mimouni, S. Perrier, I. Pointud, J. Juillard, J. Sol. Chem. 22, 769 (1993)CrossRefGoogle Scholar
  9. [9]
    M. Mimouni, M. Hebrant, G. Dauphin, J. Juillard, J. Chem. Res. S6, 278 (1996)Google Scholar
  10. [10]
    F.G. Riddell, Chirality 14, 121 (2002)CrossRefGoogle Scholar
  11. [11]
    W.H. Park et al., Intern. J. Cancer 101, 235 (2002)CrossRefGoogle Scholar
  12. [12]
    W.H. Park et al., Brit. J. Haem. 119, 400 (2002)CrossRefGoogle Scholar
  13. [13]
    W.H. Park et al., Intern. J. Oncol. 22, 377 (2003)Google Scholar
  14. [14]
    W.H. Park et al., Intern. J. Oncol. 22, 855 (2003)Google Scholar
  15. [15]
    W.H. Park, E.S. Kim, B.K. Kim, Y.Y. Lee, Intern. J. Oncology 23, 197 (2003)Google Scholar
  16. [16]
    J. Basque, M. Martel, R. Leduc, A.M. Cantin, Can. J. Physiol. Pharmacol. 86, 606 (2008)CrossRefGoogle Scholar
  17. [17]
    G.C. Blobe, W.P. Schiemann, H.F. Lodish, N. Engl. J. Med. 342, 1350 (2000)CrossRefGoogle Scholar
  18. [18]
    T. Griffin et al., J. Natl. Cancer Inst. 85, 292 (1993)CrossRefGoogle Scholar
  19. [19]
    M.S. Shaik, T.L. Jackson, M. Singh, J. Pharm. Pharmacol. 55, 819 (2003)CrossRefGoogle Scholar
  20. [20]
    M. Wu, Br. J. Cancer. 75, 1347 (1997)CrossRefGoogle Scholar
  21. [21]
    M. Sehested, T. Skovsgaard, H. Roed, Biochem. Pharmacol. 37, 3305 (1988)CrossRefGoogle Scholar
  22. [22]
    W.D. Klohz, R.W. Steinkampf, Mol. Pharmacol. 34, 180 (1988)Google Scholar
  23. [23]
    N.K. Chirase, L.W. Greene, G.T. Schelling, F.M. Byers, J. Anim. Sci. 65, 1633 (1987)Google Scholar
  24. [24]
    K.A. Johnson, Diss. Abstr., Intern. B Sci. Eng. 48, 1855 (1988)Google Scholar
  25. [25]
    S.A. Hamidinia et al., J. Biol. Chem. 277, 38111 (2002)CrossRefGoogle Scholar
  26. [26]
    I.N. Pantcheva et al., Curr. Drug Discov. Techn. 5, 154 (2008)CrossRefGoogle Scholar
  27. [27]
    I.N. Pantcheva et al., BioMetals 23, 59 (2010)CrossRefGoogle Scholar
  28. [28]
    I.N. Pantcheva et al., Inorg. Chim. Acta 363, 1879 (2010)CrossRefGoogle Scholar
  29. [29]
    J. Ivanova et al., Centr. Eur. J. Chem. 8, 852 (2010)CrossRefGoogle Scholar
  30. [30]
    R.I. Alexandrova, T. Zhivkova, I.N. Pantcheva, M.Io. Mitewa, Intern. J. Biol. Biomed. Eng. 5, 93 (2011)Google Scholar
  31. [31]
    M. R. Boyd, In: B. Teicher (Ed.), Anticancer Drug Development Cuide: Preclinical Screening, Clinical Trials and Approval (Humana Press Inc., Totowa, NJ, 1995) 23Google Scholar
  32. [32]
    A. Perzelova et al., Neoplasma 42, 25 (1998)Google Scholar
  33. [33]
    T. Mosmann, J. Immunol. Meth. 65, 55 (1983)CrossRefGoogle Scholar
  34. [34]
    E. Borenfreund, J. Puerner, Toxicol. Lett. 24, 119 (1985)CrossRefGoogle Scholar
  35. [35]
    K. Saotome, H. Morita, M. Umeda, Toxicol. In Vitro 3, 317 (1989)CrossRefGoogle Scholar
  36. [36]
    S.I.A. Wahab et al., J. Biomed. Biotechnol. 769568 (2009)Google Scholar
  37. [37]
    B.C. Pressman, M. Fashin, Ann. Rev. Pharm. Toxicol. 22, 465 (1982)CrossRefGoogle Scholar
  38. [38]
    K. Nakazato, Y. Hatano, Biochim. Biophys. Acta 1064, 103 (1991)CrossRefGoogle Scholar
  39. [39]
    W.H. Zhu, T T. Loh, Biochim. Biophys. Acta — Mol. Cell Res. 1269, 122 (1995)CrossRefGoogle Scholar
  40. [40]
    S. Grinstein, D. Rotin, M.J. Mason, Biochim. Biophys. Acta 988, 73 (1989)CrossRefGoogle Scholar
  41. [41]
    M. Bental, C. Deutsch, Am. J. Physiol. 266, 541C (1994)Google Scholar
  42. [42]
    G.N. Rao, N. de Roux, C. Sardet, J. Pouyssegur, B.C. Berk, J. Biol. Chem. 266, 13485 (1991)Google Scholar
  43. [43]
    J.M. Cobo et al., J. Cell. Physiol. 175, 59 (1998)CrossRefGoogle Scholar
  44. [44]
    S.W. Jacob, In: S.W. Jakob, E.E. Rosenbaun, D.C. Wood (Eds.), Dimethyl sulfoxide, vol. 1. Basic concepts of DMSO (Marcel Dekker Ink., New York, 1971) 99Google Scholar
  45. [45]
    N.C. Santos, J. Figueira-Coelho, J. Martins-Silva, C. Saldanha, Biochem. Pharm. 65, 1035 (2003)CrossRefGoogle Scholar
  46. [46]
    K.S. Smalley, M. Lioni, M. Herlyn, In Vitro Cell Dev. Biol. — Animal 42, 242 (2006)CrossRefGoogle Scholar
  47. [47]
    J. Lee et al., Small 5, 1213 (2009)Google Scholar
  48. [48]
    A.C. Souza et al., J. Vet. Med. A — Physiol. Pathol. Clin. Med. 52, 230 (2005)CrossRefGoogle Scholar
  49. [49]
    R. Alexandrova, Exp. Pathol. Parasitol. 4, 57 (2001)Google Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Wien 2012

Authors and Affiliations

  • Radostina I. Alexandrova
    • 1
  • Tanya Zhivkova
    • 1
  • Marin Alexandrov
    • 1
  • Georgi Miloshev
    • 2
  • Milena Georgieva
    • 2
  • Ivayla N. Pantcheva
    • 3
    Email author
  • Mariana Io. Mitewa
    • 3
  1. 1.Institute of Experimental Morphology, Pathology and Anthropology with MuseumBulgarian Academy of SciencesSofiaBulgaria
  2. 2.Institute of Molecular BiologyBulgarian Academy of SciencesSofiaBulgaria
  3. 3.Department of Analytical Chemistry, Faculty of Chemistry and PharmacySofia UniversitySofiaBulgaria

Personalised recommendations